Taiwan Bio Therapeutics (ROCO:6892) FCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6892 Taiwan Bio Therapeutics Inc ROCO:6892
22 GF Score
Price NT$26.90
GF Value NT$14.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Taiwan Bio Therapeutics FCF Margin %?

Taiwan Bio Therapeutics ROCO:6892 +0.94% 22 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates ROCO:6892 with a GF Score™ of 22/100 and a GF Value™ of NT$14.66 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 950 Biotechnology companies, Taiwan Bio Therapeutics ranks worse than 64.42% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Taiwan Bio Therapeutics's Free Cash Flow for the three months ended in Dec. 2025 was NT$0.0 Mil. Taiwan Bio Therapeutics's Revenue for the three months ended in Dec. 2025 was NT$0.0 Mil. Therefore, Taiwan Bio Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Taiwan Bio Therapeutics's current FCF Yield % is -11.89%.

The historical rank and industry rank for Taiwan Bio Therapeutics's FCF Margin % or its related term are showing as below:

ROCO:6892' s FCF Margin % Range Over the Past 10 Years
Min: -861.06   Med: -484.7   Max: -293.37
Current: -293.37

During the past 7 years, the highest FCF Margin % of Taiwan Bio Therapeutics was -293.37%. The lowest was -861.06%. And the median was -484.70%.

ROCO:6892's FCF Margin % is ranked worse than
64.42% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs ROCO:6892: -293.37

Taiwan Bio Therapeutics FCF Margin % Related Terms

Taiwan Bio Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Taiwan Bio Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Bio Therapeutics FCF Margin % Chart

Taiwan Bio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -861.06 -498.74 -334.37 -345.65 -484.70

Taiwan Bio Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -679.19 -146.28 -567.77 -439.86 0.00

ROCO:6892 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Taiwan Bio Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Taiwan Bio Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics's FCF Margin % falls into.


ROCO:6892
22GF Score
Taiwan Bio Therapeutics Inc ROCO:6892
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Bio Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Taiwan Bio Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-244.417/50.426
=-484.70 %

Taiwan Bio Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Taiwan Bio Therapeutics (ROCO:6892) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Taiwan Bio Therapeutics and its competitors. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #612 out of 950 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Taiwan Bio Therapeutics' FCF Margin % too high?
Taiwan Bio Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Taiwan Bio Therapeutics ranks #612 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #612 out of 950 companies for FCF Margin %. This places Taiwan Bio Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Taiwan Bio Therapeutics and its competitors. Taiwan Bio Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.66, compared to a current price of NT$26.90 — trading 83.5% above its estimated fair value. The current FCF Margin % is 0.00%. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued. The current stock price of NT$26.90 is trading 83.5% above its estimated GF Value™ of NT$14.66. GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.

Key valuation signals for ROCO:6892:

  • FCF Margin %: 0.00%
  • GF Value™: NT$14.66 vs. price of NT$26.90 (83.5% above fair value)
  • GF Score™: 22/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Bio Therapeutics Business Description

Address Tiding Avenue, 5th Floor, No. 501, Section 2, Neihu District, Zhubei, TWN, 114744
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score

Get the complete analysis for ROCO:6892

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.90
Price
NT$14.66
GF Value